Effects of simvastatin, atorvastatin, ezetimibe, and ezetimibe+simvastatin combination on the inflammatory process and on the liver metabolic changes of arthritic rats

Fundamental and Clinical Pharmacology

Volumn 26, Issue 6, 2012, Pages 722-734

  Bracht, Lívia ^a   Barbosa, Carmem Patrícia ^a   Caparroz Assef, Silvana Martins ^a   Cuman, Roberto Kenji Nakamura ^a   Ishii Iwamoto, Emy Luiza ^a   Bracht, Adelar ^a   Bersani Amado, Ciomar Aparecida ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Adjuvant arthritis; Atorvastatin; Ezetimibe; Ezetimibe+simvastatin combination; Liver metabolism; Simvastatin

Indexed keywords

ALANINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FREUND ADJUVANT; GLUCOSE; SIMVASTATIN;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; GLUCONEOGENESIS; INFLAMMATION; KIDNEY SIZE; LEUKOCYTE COUNT; LEUKOCYTE DIFFERENTIAL COUNT; LIVER METABOLISM; LIVER PERFUSION; LIVER SIZE; MONOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT; SPLEEN SIZE; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; AZETIDINES; DRUG THERAPY, COMBINATION; HEPTANOIC ACIDS; LEUKOCYTE COUNT; LEUKOCYTES; LIVER; LIVER FUNCTION TESTS; PERFUSION; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN;

EID: 84867989345     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00976.x     Document Type: Article

References (39)

1. Firestein G.S. Evolving concepts of reumathoid arthritis. Nature (2003) 423 356-361.
2. Walsmith J., Roubenoff R. Cachexia in reumathoid arthritis. Int. J. Cardiol. (2002) 85 89-99.
3. Youssef S., Stüve O., Patarroyo J.C. et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature (2002) 420 78-84.
4. Leung B.P., Sattar N., Crilly A. et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol. (2003) 170 1524-1530.
5. Barsante M.M., Roffê E., Yokoro C.M. et al. Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur. J. Pharmacol. (2005) 516 282-289.
6. McCarey D.W., McInnes I., Madhok R. et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (2004) 363 2015-2021.
7. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol. Sci. (2002) 23 482-487.
8. Wang C., Liu P., Liao J.K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol. Med. (2007) 14 37-44.
9. Melani L., Mills R., Hassman D. et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur. Heart J. (2003) 24 717-728.
10. Kerzner B., Corbelli J., Sharp S. et al. Efficacy and safety of ezetimibe coadministered with lovastatin in patients with primary hypercholesterolemia. Am. J. Cardiol. (2003) 91 418-424.
11. Ballantyne C.M., Ouri J., Notarbartolo A. Efficacy and safety of ezetimibe coadministered with atorvastatin in 628 in patients with primary hypercholesterolemia. Circulation (2003) 107 2409-2415.
12. Davidson M.H., Mcgarry T., Bettis R. et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. (2002) 40 2125-2134.
13. Pearson T., Ballantyne C., Sisk C., Shah A., Veltri E., Maccubbin D. Comparison of effects of ezetimibe + simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am. J. Cardiol. (2007) 15 1706-1713.
14. Palmer G., Chobaz V., Talabot-Ayer D. et al. Assessment of the efficacy of different statins in murine collagen-induced arthritis. Arthritis Rheum. (2004) 50 4051-4059.
15. Pearson C.M. Development of arthritis, periarthritis, and periostitis in rats given adjuvants. Proc. Soc. Exp. Biol. Med. (1956) 91 95-101.
16. Billingham M.E. Models of arthritis and the search for anti-arthritic drugs. Pharmacol. Ther. (1983) 21 389-428.
17. Rainsford K.D. Editorial: Adjuvant polyarthritis in rats: is this a satisfactory model for screening anti-arthritic drugs? Agents Actions (1982) 12 452-458.
18. Donaldson L.F., Seckl J.R., McQueen D.S. A discrete adjuvant-induced monoarthritis in the rat: effects of adjuvant dose. J. Neurosci. Methods (1993) 49 5-10.
19. Caparroz-Assef S.M., Bersani-Amado C.A., Nascimento E.A., Kelmer-Bracht A.M., Ishii-Iwamoto E.L. Effects of the nonsteroidal anti-inflammatory drug nimesulide on energy metabolism in livers from adjuvant-induced arthritic rats. Res. Commun. Mol. Pathol. Pharmacol. (1998) 99 93-116.
20. Fedatto-Júnior Z., Kelmer-Bracht A.M., Ishii-Iwamoto E.L., Constantin J., Bracht A. Gluconeogenesis in the liver of arthritic rats. Cell Biochem. Funct. (1999) 17 271-278.
21. Fedatto-Júnior Z., Ishii-Iwamoto E.L., Caparroz-Assef S.M., Vicentini G.E., Bracht A., Kelmer-Bracht A.M. Glycogen levels and glycogen catabolism in livers from arthritic rats. Mol. Cell. Biochem. (2002) 229 1-7.
22. Fedatto-Júnior Z., Ishii-Iwamoto E.L., Bersani Amado C.A. et al. Glucose phosphorylation capacity and glycolysis in the liver of arthritic rats. Inflamm. Res. (2000) 49 128-132.
23. Yassuda P., Bracht A., Ishii-Iwamoto E.L., Lousano S.H., Bracht L., Kelmer-Bracht A.M. The urea cycle in the liver of arthritic rats. Mol. Cell. Biochem. (2003) 243 97-106.
24. Caparroz-Assef S.M., Bersani-Amado C.A., Kelmer-Bracht A.M., Bracht A., Ishii-Iwamoto E.L. The metabolic changes caused by dexamethasone in the adjuvant-induced arthritic rat. Mol. Cell. Biochem. (2007) 302 87-98.
25. Kelmer-Bracht A.M., Broetto-Biazon A.C., Sá-Nakanishi A.B., Ishii-Iwamoto E.L., Bracht A. Low doses of tumor necrosis factor α and interleukin 1β diminish hepatic gluconeogenesis from alanine in vivo. Basic Clin. Pharmacol. Toxicol. (2006) 99 335-339.
26. Silva M.A.R.C.P., Bersani-Amado C.A., Iwamoto E.L.I., Bracht L., Caparroz-Assef S.M. Protective effects of indomethacin and cyclophosphamide but not of infliximab on liver metabolic changes caused by adjuvant-induced arthritis. Inflammation (2010) in press.
27. Winder C.V., Wax J., Been M.A. Rapid foot volume measurements on unanesthetized rats and question of the phenylbutazone effect on anaphilactoid oedema. Arch. Int. Pharmacodyn. Ther. (1957) 112 174-187.
28. Scholz R., Bücher T. Hemoglobin-free perfusion of rat liver, in: Chance B., Estabrook R.W., Williamson J.R. (Eds), Control of energy metabolism, Academic Press, New York, USA, 1965, pp. 393-414.
29. Kelmer-Bracht A.M., Ishii E.L., de Andrade P.V.M., Bracht A. Construction of a liver perfusion apparatus for studies on metabolic regulation and mechanisms of drug action. Braz. Arch. Biol. Technol. (1984) 27 419-438.
30. Bergmeyer H.U., Bernt E. Determination of d-glucose with glucose oxidase and peroxidase, in: Bergmeyer H.U. (Ed.), Methods of enzymatic analysis, Academic Press, New York, USA, 1974, pp. 1205-1215.
31. +, in: Bergmeyer H.U. (Ed.), Methods of enzymatic analysis, Academic Press, New York, USA, 1974, pp. 1464-1468.
32. Czok R., Lamprecht W. Pyruvate, phosphoenolpyruvate and d-glycerate-2-phosphate, in: Bergmeyer H.U. (Ed.), Methods of enzymatic analysis, Academic Press, New York, USA, 1974, pp. 1446-1451.
33. Kun F., Kearney E.B. Ammonia, in: Bergmeyer H.U. (Ed.), Methods of enzymatic analysis, Academic Press, New York, USA, 1974, pp. 1802-1806.
34. Rosenthale M.E., Capetola R.J. Adjuvant arthritis: imunopathological and hyperalgesic features. Fed. Proc. (1982) 41 2577-2582.
35. Bolon B., Campagnuolo G., Zhu L., Duryea D., Zack D., Feige U. Interleukin-1β and tumor necrosis factor-α produce distinct, time-dependent patterns of acute arthritis in the rat knee. Vet. Pathol. (2004) 41 235-243.
36. Sager P.T., Melani L., Lipka L. et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am. J. Cardiol. (2003) 92 1414-1418.
37. Ballarè M., Campanini M., Airoldi G. et al. Hepatotoxicity of hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors. Minerva Gastroenterol. Dietol. (1992) 38 41-44.
38. Bhardwaj S.S., Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin. Liver Dis. (2007) 11 597-613.
39. Yang S.J., Choi J.M., Kim L. et al. Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes. Biochem. Biophys. Res. Commun. (2011) 407 153-157.